Track record · closed signal

Pfizer Inc. (PFE) — closed signal from August 10, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 8, 2025.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted
$24.15 Published $27.06 Target $24.43 Window close $27.21 Peak
$23.27 – $24.05Entry zone — fair-value band
$24.15Published — price the day we called it
$27.06Target — the price the thesis aimed for
$27.21Peak — highest point inside the window, not a realized return
$24.43Window close — end-of-window price, context only

What happened

Target reached

Hit or exceeded the predicted growth inside the window.

Peak price
$27.21
peak on October 3, 2025 — not a realized return
Peak gain
+12.7%
peak, from the publication price
Window close
$24.43
end-of-window price, context only
Days to target
Window
August 10, 2025 – November 8, 2025

The thesis — published August 10, 2025

Predicted growth
+14%
over the measurement window
Target price
$27.06
the price the thesis aimed for
Entry zone
$23.27 – $24.05
the fair-value band we waited for
Price at publication
$24.15
published August 10, 2025
Confidence
69%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Pfizer offers a steady option because it pays close to a 7% dividend, so investors get income while they wait. Hopes for lower interest rates have lifted markets, which can help this kind of stock. Buying interest has picked up and the recent average price is leveling, which could support a slow move up over the next 0-3 months. Trial and pricing headlines are risks, so use modest size.

Primary drivers

  • Near 7% dividend pays you to wait and can steady the share price
  • Long record of paying dividends was recently highlighted by analysts
  • Investor mood improved; recent average price is leveling, showing stability
  • Expectations for lower interest rates often help steady, income-focused stocks

How it played out

PFE: target reached, then faded by the end

Lyra published PFE on 2025-08-10 at 24.15, with 14% expected growth and a target of 27.06. The thesis pointed to a near 7% dividend, a long dividend record, improved investor mood, a leveling recent average price, and hopes for lower interest rates helping steady income stocks.

Inside the window from 2025-08-10 to 2025-11-08, PFE peaked at 27.21 on 2025-10-03, above the 27.06 target. The peak gain was 12.7%. It did not hold there. The window ended at 24.43. The thesis played out on the target touch, but not on the finish.

What happened during the window

On September 30, 2025, Pfizer and the Trump administration announced a drug-pricing agreement tied to Medicaid pricing and a direct purchasing platform. Reuters reported that Pfizer posted third-quarter results on November 4, 2025, inside the measurement window.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.